elastic
发表于 2025-3-30 09:49:02
http://reply.papertrans.cn/23/2250/224970/224970_51.png
溺爱
发表于 2025-3-30 15:01:36
https://doi.org/10.1007/978-3-642-24440-7eatment strategy for B-CLL. The addition of anti-CD20 antibody to its management has remarkably improved the survival of B-CLL patients. Fludarabine, cyclophosphamide, and rituximab (FCR) is a standard treatment for physically fit patients without . defects, while bendamustine and rituximab (BR) is
意见一致
发表于 2025-3-30 17:56:08
http://reply.papertrans.cn/23/2250/224970/224970_53.png
DEAF
发表于 2025-3-30 21:50:08
http://reply.papertrans.cn/23/2250/224970/224970_54.png